Harry Gillis
Stock Analyst at Berenberg Bank
(4.35)
# 1,272
Out of 4,574 analysts
82
Total ratings
63%
Success rate
19.7%
Average return
Main Sectors:
Stocks Rated by Harry Gillis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Buy | €270.00 | €221.00 | +22.17% | 5 | Jul 24, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | $14 → $7.45 | $7.18 | +3.76% | 13 | Jul 20, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 550.00 → kr 575.00 | kr 457.40 | +25.71% | 23 | Jul 16, 2026 | |
| QGEN Qiagen | Downgraded: Hold | $57 → $46 | $41.37 | +9.99% | 8 | Jul 14, 2026 | |
| SWX: TECN Tecan Group AG | Maintained: Buy | CHF 205.00 → CHF 220.00 | CHF 182.20 | +20.75% | 11 | Jul 9, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $155 → $140 | $89.33 | +56.72% | 12 | May 11, 2026 | |
| MRNA Moderna | Maintained: Hold | $26 → $32 | $54.07 | -40.82% | 10 | Jan 22, 2026 |
Sartorius Aktiengesellschaft
Jul 24, 2026
Maintained: Buy
Price Target: €270.00
Current: €221.00
Upside: +22.17%
AtaiBeckley
Jul 20, 2026
Downgraded: Hold
Price Target: $14 → $7.45
Current: $7.18
Upside: +3.76%
Swedish Orphan Biovitrum AB (publ)
Jul 16, 2026
Maintained: Buy
Price Target: kr 550.00 → kr 575.00
Current: kr 457.40
Upside: +25.71%
Qiagen
Jul 14, 2026
Downgraded: Hold
Price Target: $57 → $46
Current: $41.37
Upside: +9.99%
Tecan Group AG
Jul 9, 2026
Maintained: Buy
Price Target: CHF 205.00 → CHF 220.00
Current: CHF 182.20
Upside: +20.75%
BioNTech SE
May 11, 2026
Maintained: Buy
Price Target: $155 → $140
Current: $89.33
Upside: +56.72%
Moderna
Jan 22, 2026
Maintained: Hold
Price Target: $26 → $32
Current: $54.07
Upside: -40.82%